Emergent BioSolutions director sells stock, gets awards
Emergent BioSolutions director Sujata Tyagi reported a mix of stock awards and tax-related sales.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Emergent BioSolutions director Sujata Tyagi reported a mix of stock awards and tax-related sales. On April 30, 2026, she received an annual grant of 25,344 restricted stock units and 11,296 stock options with a $7.99 exercise price, vesting in one year for continued board service. On May 1, 2026, she sold a total of 13,761 common shares in open-market trades at weighted average prices around the $8–$9 range under a pre-arranged Rule 10b5-1 trading plan to cover taxes from RSU vesting. Following these transactions, she continues to directly hold 100,563 common shares of Emergent BioSolutions.
Insider Trade Summary 10b5-1
Net Seller: 13,761 shares
Net Sell
4 txns
Insider
Dayal Sujata Tyagi
Role
Director
Sold
13,761 shs ($116K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 12,781 | $8.36 | $107K |
| Sale | Common Stock | 980 | $8.94 | $9K |
| Grant/Award | Stock Option (Right to Buy) | 11,296 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 25,344 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 11,296 contracts (Direct);
Common Stock — 100,563 shares (Direct)
Footnotes (6)
- F1. Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.
- F2. Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated August 8, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026.
- F3. The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $7.70 to $8.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F4. The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $8.70 to $8.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F5. Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.
- F6. The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
Key Figures
RSU grant: 25,344 shares
Option grant: 11,296 options
Option exercise price: $7.99/share
+4 more
7 metrics
RSU grant
25,344 shares
Annual director RSU grant on April 30, 2026
Option grant
11,296 options
Director stock options granted April 30, 2026
Option exercise price
$7.99/share
Exercise price for 11,296 stock options
Options expiration
April 30, 2033
Expiration date of granted stock options
Shares sold
13,761 shares
Total common shares sold May 1, 2026
Sale price ranges
$7.70–$8.69 and $8.70–$8.99
Weighted-average price bands for May 1, 2026 sales
Post-transaction holdings
100,563 shares
Common shares held directly after reported transactions
Key Terms
restricted stock units, Rule 10b5-1 trading plan, Stock Incentive Plan, weighted average price, +1 more
5 terms
restricted stock units financial
"Represents an annual grant of restricted stock units ("RSUs") granted under"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Rule 10b5-1 trading plan regulatory
"Shares were sold pursuant to a Rule 10b5-1 trading plan, dated"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Incentive Plan financial
"granted under the Company's Stock Incentive plan, as amended and restated"
A stock incentive plan is a company program that gives employees or directors pieces of ownership or the right to buy shares over time, similar to receiving a bonus paid in company stock instead of cash. Investors pay attention because these plans align staff incentives with long‑term company performance but can also dilute existing shareholders and affect reported profits when grants are expensed, so they influence both ownership percentages and financial results.
weighted average price financial
"The price reported in Column 4 is a weighted average price for sales"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Black-Scholes value financial
"dividing by the Black-Scholes value of a single option calculated"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Emergent BioSolutions (EBS) director Sujata Tyagi receive in this Form 4 filing?
She received an annual grant of 25,344 restricted stock units and 11,296 stock options on April 30, 2026. These awards were made under Emergent BioSolutions’ Stock Incentive Plan for board and committee service and vest after one year of continued board membership.
At what price can the new stock options for Emergent BioSolutions (EBS) be exercised?
The newly granted stock options have an exercise price of $7.99 per share. Each option allows the purchase of one share of Emergent BioSolutions common stock after vesting, with the options scheduled to expire on April 30, 2033 if not exercised earlier.
How and when do the new RSUs and options for Emergent BioSolutions (EBS) vest?
Both the 25,344 RSUs and 11,296 stock options vest on the day before the one-year anniversary of the April 30, 2026 grant date. Vesting is conditioned on Sujata Tyagi continuing to serve on Emergent BioSolutions’ board of directors through that date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates